The Eurocyst Initiative: Building a Network of ADPKD Reference Centers Across Europe

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

1100 participants

Study Classification

OBSERVATIONAL

Study Start Date

2013-08-31

Study Completion Date

2016-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

EuroCYST initiative aims to build a large, well-characterized cohort of Autosomal Dominant polyCYSTic Kidney Disease (ADPKD) subjects who are followed in a longitudinal observational cohort study has the potential to identify progression factors and biomarkers, and to assess disease stage specific mortality, morbidity and health care costs.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Observational Study in Patients With Autosomal Dominant Polycystic Kidney Disease

NCT01430494

Autosomal Dominant Polycystic Kidney Disease (ADPKD)

COMPLETED

Analysis of Patients With Autosomal Dominant Polycystic Kidney

NCT06759142

Autosomal Dominant Polycystic Kidney ADPKD

RECRUITING

A Study Measuring Quality of Life, Treatment Preference and Satisfaction of ADPKD Patients in Europe

NCT02848521

Autosomal Dominant Polycystic Kidney Disease

UNKNOWN

Artificial Intelligence-based Image Processing Methods to Advance the Characterization of Polycystic Kidney Disease

NCT06688981

Autosomal Dominant Polycystic Kidney Disease (ADPKD)

ACTIVE_NOT_RECRUITING

Analysis of Clinical and Molecular Genetic Data Influencing the Evolution and Response to Therapy of ADPKD Patients (Autosomal Dominant Polycystic Kidney Disease)

NCT02887729

Autosomal Dominant Polycystic Kidney Disease

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The EuroCYST Initiative aims to build a network of ADPKD reference centers across Europe and to establish a large-scale observational cohort of ADPKD patients for the purpose of studying the pathogenesis, rate of disease progression, progression rate modifiers, disease stage specific morbidity, mortality, health economic issues and the predictive value of biomarkers in ADPKD. Overall 1,100 patients will be enrolled in 14 study sites across Europe and will be followed up for at least three years. The ADPKD reference center network across Europe and the observational cohort study will enable European ADPKD researchers to gain insight into the natural history, heterogeneity and associated complications of the disease as well as how it affects the lives of patients across Europe.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Autosomal Dominant Polycystic Kidney Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

ADPKD

EuroCYST is and observational trail aiming to investigate disease progression across the different stages of disease and stage specific morbidity and mortality factors in a longitudinal observational multi center study and to evaluate the levels of and associations between the impacts of patients reported disease outcome (quality of life (QoL), pain, self-estimated health status, health burden).

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Participants ≥ 18 years;
* Clinical diagnosis of ADPKD based on kidney imaging and family history;
* Estimated Glomerular Filtration Rate (eGFR) ≥ 30 ml/min/1.73m2 (Chronic Kidney Disease Epidemiology Collaboration(CKD-EPI)- formula);
* Provided written informed consent.

Exclusion Criteria

* Receiving chronic renal replacement therapy before enrollment (dialysis, allograft) or anticipated in the following 12 months after enrollment;
* Participation in a clinical trial aiming to modify disease outcome one year or less before enrollment in the EuroCYST study;
* New York Heart Association (NYHA) stadium IV.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No